Supplement 6 **Forest plots of adverse events**

Systemic vs. Placebo

a. Infection & respiratory system p. 2-12
b. Gastro-intestinal tract p. 13-22
c. CNS & behaviour effects p. 23-29
d. Dermatologic conditions p. 30-32
e. Endocrine/ metabolic & musculoskeletal systems p. 33-35
f. Cardiovascular system p. 36-38
g. General adverse events/ other symptoms p. 39-40
h. Immune system & oncology p. 41

Inhaled vs. Placebo

a. Infection & respiratory system p. 42-47
b. Gastro-intestinal tract p. 48-51
c. CNS & behaviour effects p. 52-54
d. Dermatologic conditions p. 55-57
e. Endocrine/ metabolic & musculoskeletal systems p. 58
f. Cardiovascular system p. 59

Dexamethasone vs. Other steroid

a. Gastro-intestinal tract p. 60-63
b. CNS & behaviour effects p. 64-66
c. Dermatologic conditions p. 67
d. Endocrine/ metabolic & musculoskeletal systems p. 68
e. Cardiovascular system p. 69
f. General adverse events/ other symptoms p. 70-71

SYSTEMIC vs. PLACEBO – Infection & Respiratory

Severe infections



Severe infections – Peto



Severe infections (by dose)



Severe infections (by dose) – Peto



Severe infections (by condition)



Severe infections (by condition) – Peto

Study or Subgroup	Systemic Events	Systemic Total	Placebo Events	Placebo Total	Weight	Peto Odds Ratio Peto, Fixed, 95% CI
1.26.1 Bronchiolitis						
Leer 1969	0	148	0	149		Not estimable
Sussman 1964	0	31	0	26		Not estimable
Subtotal (95% CI)		**179**		**175**		**Not estimable**
Total events	0		0			
Heterogeneity: Not applicable						
Test for overall effect: Not applicable						
1.26.2 Croup						
Bjornson 2004	0	359	1	361	50.4%	0.14 [0.00, 6.86]
Sumboonnanonda 1997	0	14	1	18	49.6%	0.17 [0.00, 8.79]
Subtotal (95% CI)		**373**		**379**	**100.0%**	**0.15 [0.01, 2.45]**
Total events	0		2			
Heterogeneity: Chi² = 0.01, df = 1 (P = 0.94); I² = 0%						
Test for overall effect: Z = 1.33 (P = 0.18)						
Total (95% CI)		**552**		**554**	**100.0%**	**0.15 [0.01, 2.45]**
Total events	0		2			
Heterogeneity: Chi² = 0.01, df = 1 (P = 0.94); I² = 0%						
Test for overall effect: Z = 1.33 (P = 0.18)						
Test for subgroup differences: Not applicable						



Systemic infections

Study or Subgroup	Systemic Events	Systemic Total	Placebo Events	Placebo Total	Weight	Risk Difference M-H, Random, 95% CI
Bjornson 2004	5	359	4	361	7.8%	0.00 [-0.01, 0.02]
Corneli 2007	0	305	0	295	48.4%	0.00 [-0.01, 0.01]
Daugbjerg 1993	0	31	0	27	0.5%	0.00 [-0.07, 0.07]
Plint 2009	0	200	0	199	21.5%	0.00 [-0.01, 0.01]
Plint 2009	0	200	0	201	21.7%	0.00 [-0.01, 0.01]
Total (95% CI)		**1095**		**1083**	**100.0%**	**0.00 [-0.00, 0.00]**
Total events	5		4			
Heterogeneity: Tau² = 0.00; Chi² = 0.21, df = 4 (P = 1.00); I² = 0%						
Test for overall effect: Z = 0.10 (P = 0.92)						



Systemic infections – Peto

Study or Subgroup	Systemic Events	Systemic Total	Placebo Events	Placebo Total	Weight	Peto Odds Ratio Peto, Fixed, 95% CI
Bjornson 2004	5	359	4	361	100.0%	1.26 [0.34, 4.68]
Corneli 2007	0	305	0	295		Not estimable
Daugbjerg 1993	0	31	0	27		Not estimable
Plint 2009	0	200	0	199		Not estimable
Plint 2009	0	200	0	201		Not estimable
Total (95% CI)		**1095**		**1083**	**100.0%**	**1.26 [0.34, 4.68]**
Total events	5		4			
Heterogeneity: Not applicable						
Test for overall effect: Z = 0.34 (P = 0.73)						



Systemic infections (by dose)



Systemic infections (by dose) – Peto



Systemic infections (by condition)



Systemic infections (by condition) – Peto



Lung/trachea



Lung/trachea – Peto



Lung/trachea (by dose)



Lung/trachea (by dose) – Peto



Lung/trachea (by condition)



Lung/trachea (by condition) – Peto



URT



URT – Peto



URT (by dose)

Study or Subgroup	Systemic Events	Systemic Total	Placebo Events	Placebo Total	Weight	Risk Difference M-H, Random, 95% CI
1.41.1 Single Dose						
Bjornson 2004	0	359	0	361	94.7%	0.00 [-0.01, 0.01]
Gill 2017	1	22	0	5	0.0%	0.05 [-0.20, 0.29]
Johnson 1998	0	47	0	49	1.8%	0.00 [-0.04, 0.04]
Klassen 1998	0	64	1	65	1.6%	-0.02 [-0.06, 0.03]
Subtotal (95% CI)		**492**		**480**	**98.1%**	**-0.00 [-0.01, 0.01]**
Total events	1		1			
Heterogeneity: Tau² = 0.00; Chi² = 0.80, df = 3 (P = 0.85); I² = 0%						
Test for overall effect: Z = 0.08 (P = 0.93)						
1.41.2 Multi-Dose						
Daugbjerg 1993	0	31	0	27	0.7%	0.00 [-0.07, 0.07]
Leer 1969	8	148	6	149	1.2%	0.01 [-0.03, 0.06]
Subtotal (95% CI)		**179**		**176**	**1.9%**	**0.01 [-0.03, 0.05]**
Total events	8		6			
Heterogeneity: Tau² = 0.00; Chi² = 0.13, df = 1 (P = 0.72); I² = 0%						
Test for overall effect: Z = 0.45 (P = 0.65)						
Total (95% CI)		**671**		**656**	**100.0%**	**-0.00 [-0.01, 0.01]**
Total events	9		7			
Heterogeneity: Tau² = 0.00; Chi² = 1.65, df = 5 (P = 0.89); I² = 0%						
Test for overall effect: Z = 0.02 (P = 0.98)						
Test for subgroup differences: Chi² = 0.21, df = 1 (P = 0.65), I² = 0%						



URT (by dose) – Peto

Study or Subgroup	Systemic Events	Systemic Total	Placebo Events	Placebo Total	Weight	Peto Odds Ratio Peto, Fixed, 95% CI
1.42.1 Single Dose						
Bjornson 2004	0	359	0	361		Not estimable
Gill 2017	1	22	0	5	4.0%	3.41 [0.02, 530.01]
Johnson 1998	0	47	0	49		Not estimable
Klassen 1998	0	64	1	65	6.7%	0.14 [0.00, 6.93]
Subtotal (95% CI)		**492**		**480**	**10.7%**	**0.46 [0.02, 10.18]**
Total events	1		1			
Heterogeneity: Chi² = 0.97, df = 1 (P = 0.32); I² = 0%						
Test for overall effect: Z = 0.49 (P = 0.62)						
1.42.2 Multi-Dose						
Daugbjerg 1993	0	31	0	27		Not estimable
Leer 1969	8	148	6	149	89.3%	1.36 [0.47, 3.96]
Subtotal (95% CI)		**179**		**176**	**89.3%**	**1.36 [0.47, 3.96]**
Total events	8		6			
Heterogeneity: Not applicable						
Test for overall effect: Z = 0.56 (P = 0.58)						
Total (95% CI)		**671**		**656**	**100.0%**	**1.21 [0.44, 3.33]**
Total events	9		7			
Heterogeneity: Chi² = 1.39, df = 2 (P = 0.50); I² = 0%						
Test for overall effect: Z = 0.37 (P = 0.71)						
Test for subgroup differences: Chi² = 0.42, df = 1 (P = 0.52), I² = 0%						



URT (by condition)



URT (by condition) – Peto

Study or Subgroup	Systemic Events	Total	Placebo Events	Total	Weight	Peto Odds Ratio Peto, Fixed, 95% CI
1.44.1 Bronchiolitis						
Leer 1969	8	148	6	149	89.3%	1.36 [0.47, 3.96]
Subtotal (95% CI)		**148**		**149**	**89.3%**	**1.36 [0.47, 3.96]**
Total events	8		6			
Heterogeneity: Not applicable						
Test for overall effect: Z = 0.56 (P = 0.58)						
1.44.2 Croup						
Bjornson 2004	0	359	0	361		Not estimable
Gill 2017	1	22	0	5	4.0%	3.41 [0.02, 530.01]
Johnson 1998	0	47	0	49		Not estimable
Klassen 1998	0	64	1	65	6.7%	0.14 [0.00, 6.93]
Subtotal (95% CI)		**492**		**480**	**10.7%**	**0.46 [0.02, 10.18]**
Total events	1		1			
Heterogeneity: Chi² = 0.97, df = 1 (P = 0.32); I² = 0%						
Test for overall effect: Z = 0.49 (P = 0.62)						
1.44.3 Wheeze						
Daugbjerg 1993	0	31	0	27		Not estimable
Subtotal (95% CI)		**31**		**27**		**Not estimable**
Total events	0		0			
Heterogeneity: Not applicable						
Test for overall effect: Not applicable						
Total (95% CI)		**671**		**656**	**100.0%**	**1.21 [0.44, 3.33]**
Total events	9		7			
Heterogeneity: Chi² = 1.39, df = 2 (P = 0.50); I² = 0%						
Test for overall effect: Z = 0.37 (P = 0.71)						
Test for subgroup differences: Chi² = 0.42, df = 1 (P = 0.52), I² = 0%						



Voice complaints

Study or Subgroup	Systemic Events	Total	Placebo Events	Total	Weight	Risk Difference M-H, Random, 95% CI
Daugbjerg 1993	0	31	0	27	100.0%	0.00 [-0.07, 0.07]
Total (95% CI)		**31**		**27**	**100.0%**	**0.00 [-0.07, 0.07]**
Total events	0		0			
Heterogeneity: Not applicable						
Test for overall effect: Z = 0.00 (P = 1.00)						



Voice complaints – Peto

Study or Subgroup	Systemic Events	Total	Placebo Events	Total	Weight	Peto Odds Ratio Peto, Fixed, 95% CI
Daugbjerg 1993	0	31	0	27		Not estimable
Total (95% CI)		**31**		**27**		**Not estimable**
Total events	0		0			
Heterogeneity: Not applicable						
Test for overall effect: Not applicable						



SYSTEMIC vs. PLACEBO – GI

GI bleeding

Study or Subgroup	Systemic Events	Systemic Total	Placebo Events	Placebo Total	Weight	Risk Difference M-H, Random, 95% CI
Bjornson 2004	0	359	0	361	56.0%	0.00 [-0.01, 0.01]
Buckingham 2002	0	22	0	19	0.2%	0.00 [-0.09, 0.09]
Corneli 2007	0	305	0	295	38.9%	0.00 [-0.01, 0.01]
Johnson 1998	0	47	0	49	1.0%	0.00 [-0.04, 0.04]
Plint 2009	17	200	14	199	0.6%	0.01 [-0.04, 0.07]
Plint 2009	12	200	16	201	0.7%	-0.02 [-0.07, 0.03]
Roosevelt 1996	0	65	0	53	1.5%	0.00 [-0.03, 0.03]
Teeratakulpisarn 2007	2	89	1	85	1.1%	0.01 [-0.03, 0.05]
Total (95% CI)		**1287**		**1262**	**100.0%**	**0.00 [-0.00, 0.00]**
Total events	31		31			

Heterogeneity: Tau² = 0.00; Chi² = 1.20, df = 7 (P = 0.99); I² = 0%
Test for overall effect: Z = 0.04 (P = 0.97)



GI bleeding – Peto

Study or Subgroup	Systemic Events	Systemic Total	Placebo Events	Placebo Total	Weight	Peto Odds Ratio Peto, Fixed, 95% CI
Bjornson 2004	0	359	0	361		Not estimable
Buckingham 2002	0	22	0	19		Not estimable
Corneli 2007	0	305	0	295		Not estimable
Johnson 1998	0	47	0	49		Not estimable
Plint 2009	17	200	14	199	49.6%	1.23 [0.59, 2.55]
Plint 2009	12	200	16	201	45.2%	0.74 [0.34, 1.59]
Roosevelt 1996	0	65	0	53		Not estimable
Teeratakulpisarn 2007	2	89	1	85	5.1%	1.87 [0.19, 18.27]
Total (95% CI)		**1287**		**1262**	**100.0%**	**1.00 [0.60, 1.67]**
Total events	31		31			

Heterogeneity: Chi² = 1.18, df = 2 (P = 0.55); I² = 0%
Test for overall effect: Z = 0.01 (P = 0.99)



GI bleeding (by dose)



GI bleeding (by dose) – Peto



GI bleeding (by condition)



GI bleeding (by condition) - Peto



Vomiting

Study or Subgroup	Systemic Events	Systemic Total	Placebo Events	Placebo Total	Weight	Risk Difference M-H, Random, 95% CI
Bjornson 2004	3	359	4	361	19.7%	-0.00 [-0.02, 0.01]
Connett 1994	1	18	4	15	0.1%	-0.21 [-0.46, 0.04]
Connett 1994	0	19	1	18	0.2%	-0.06 [-0.19, 0.08]
Corneli 2007	17	305	14	295	3.2%	0.01 [-0.03, 0.04]
Csonka 2003	9	113	4	117	1.1%	0.05 [-0.01, 0.11]
Kuyucu 2004	0	23	0	11	0.3%	0.00 [-0.13, 0.13]
Kuyucu 2004	0	23	0	12	0.3%	0.00 [-0.12, 0.12]
Panickar 2009	1	343	0	344	62.6%	0.00 [-0.01, 0.01]
Plint 2009	2	200	4	199	7.1%	-0.01 [-0.03, 0.01]
Plint 2009	5	200	3	201	5.4%	0.01 [-0.02, 0.04]
Total (95% CI)		**1603**		**1573**	**100.0%**	**0.00 [-0.00, 0.01]**
Total events	38		34			

Heterogeneity: Tau² = 0.00; Chi² = 7.45, df = 9 (P = 0.59); I² = 0%
Test for overall effect: Z = 0.51 (P = 0.61)



Vomiting – Peto

Study or Subgroup	Systemic Events	Systemic Total	Placebo Events	Placebo Total	Weight	Peto Odds Ratio Peto, Fixed, 95% CI
Bjornson 2004	3	359	4	361	10.1%	0.75 [0.17, 3.34]
Connett 1994	1	18	4	15	6.3%	0.20 [0.03, 1.34]
Connett 1994	0	19	1	18	1.5%	0.13 [0.00, 6.46]
Corneli 2007	17	305	14	295	42.8%	1.18 [0.57, 2.44]
Csonka 2003	9	113	4	117	17.9%	2.34 [0.76, 7.14]
Kuyucu 2004	0	23	0	11		Not estimable
Kuyucu 2004	0	23	0	12		Not estimable
Panickar 2009	1	343	0	344	1.5%	7.41 [0.15, 373.47]
Plint 2009	2	200	4	199	8.6%	0.51 [0.10, 2.54]
Plint 2009	5	200	3	201	11.4%	1.67 [0.41, 6.77]
Total (95% CI)		**1603**		**1573**	**100.0%**	**1.10 [0.69, 1.76]**
Total events	38		34			

Heterogeneity: Chi² = 8.43, df = 7 (P = 0.30); I² = 17%
Test for overall effect: Z = 0.39 (P = 0.69)



Vomiting (by dose)



Vomiting (by dose) – Peto



Vomiting (by condition)



Vomiting (by condition) – Peto



Abdominal pain



Abdominal pain – Peto



Diarrhea



Diarrhea – Peto



Diarrhea (by dose)



Diarrhea (by dose) – Peto



Diarrhea (by condition)



Diarrhea (by condition) – Peto



SYSTEMIC vs. PLACEBO – CNS & Behaviour

Tremor/jitteriness



Study or Subgroup	Systemic Events	Systemic Total	Placebo Events	Placebo Total	Weight	Risk Difference M-H, Random, 95% CI
Connett 1994	7	18	5	15	0.3%	0.06 [-0.27, 0.38]
Connett 1994	2	19	2	18	0.8%	-0.01 [-0.21, 0.19]
Goebel 2000	1	24	0	24	2.7%	0.04 [-0.07, 0.15]
Kuyucu 2004	0	23	0	11	1.9%	0.00 [-0.13, 0.13]
Kuyucu 2004	0	23	0	12	2.2%	0.00 [-0.12, 0.12]
Lin 1991	3	52	1	28	3.6%	0.02 [-0.07, 0.12]
Plint 2009	4	200	4	199	41.1%	-0.00 [-0.03, 0.03]
Plint 2009	5	200	2	201	47.4%	0.02 [-0.01, 0.04]
Total (95% CI)		**559**		**508**	**100.0%**	**0.01 [-0.01, 0.03]**
Total events	22		14			

Heterogeneity: Tau² = 0.00; Chi² = 1.23, df = 7 (P = 0.99); I² = 0%
Test for overall effect: Z = 1.01 (P = 0.31)

Tremor/jitteriness – Peto



Study or Subgroup	Systemic Events	Systemic Total	Placebo Events	Placebo Total	Weight	Peto Odds Ratio Peto, Fixed, 95% CI
Connett 1994	7	18	5	15	25.4%	1.26 [0.31, 5.13]
Connett 1994	2	19	2	18	11.9%	0.94 [0.12, 7.31]
Goebel 2000	1	24	0	24	3.3%	7.39 [0.15, 372.38]
Kuyucu 2004	0	23	0	11		Not estimable
Kuyucu 2004	0	23	0	12		Not estimable
Lin 1991	3	52	1	28	11.4%	1.58 [0.19, 12.83]
Plint 2009	4	200	4	199	25.6%	0.99 [0.25, 4.03]
Plint 2009	5	200	2	201	22.4%	2.40 [0.54, 10.68]
Total (95% CI)		**559**		**508**	**100.0%**	**1.44 [0.71, 2.92]**
Total events	22		14			

Heterogeneity: Chi² = 1.59, df = 5 (P = 0.90); I² = 0%
Test for overall effect: Z = 1.01 (P = 0.31)

Tremor/jitteriness (by dose)



Tremor/jitteriness (by dose) – Peto



Tremor/jitteriness (by condition)



Tremor/jitteriness (by condition) – Peto



Behaviour change



Behaviour change – Peto

Study or Subgroup	Systemic Events	Systemic Total	Placebo Events	Placebo Total	Weight	Peto Odds Ratio Peto, Fixed, 95% CI
Bjornson 2004	1	359	1	361	20.9%	1.01 [0.06, 16.11]
Csonka 2003	3	113	2	117	51.3%	1.56 [0.27, 9.13]
Klassen 1998	0	64	0	65		Not estimable
Lin 1991	3	52	0	28	27.8%	4.85 [0.44, 53.60]
Total (95% CI)		**588**		**571**	**100.0%**	**1.95 [0.55, 6.92]**
Total events	7		3			

Heterogeneity: Chi² = 0.83, df = 2 (P = 0.66); I² = 0%
Test for overall effect: Z = 1.03 (P = 0.30)



Behaviour change (by dose)

Study or Subgroup	Systemic Events	Systemic Total	Placebo Events	Placebo Total	Weight	Risk Difference M-H, Random, 95% CI
1.55.1 Single-dose						
Bjornson 2004	1	359	1	361	70.0%	0.00 [-0.01, 0.01]
Klassen 1998	0	64	0	65	16.5%	0.00 [-0.03, 0.03]
Subtotal (95% CI)		**423**		**426**	**86.4%**	**0.00 [-0.01, 0.01]**
Total events	1		1			

Heterogeneity: Tau² = 0.00; Chi² = 0.00, df = 1 (P = 1.00); I² = 0%
Test for overall effect: Z = 0.00 (P = 1.00)

1.55.2 Multi-dose						
Csonka 2003	3	113	2	117	11.0%	0.01 [-0.03, 0.05]
Lin 1991	3	52	0	28	2.6%	0.06 [-0.02, 0.14]
Subtotal (95% CI)		**165**		**145**	**13.6%**	**0.02 [-0.02, 0.06]**
Total events	6		2			

Heterogeneity: Tau² = 0.00; Chi² = 1.13, df = 1 (P = 0.29); I² = 11%
Test for overall effect: Z = 0.98 (P = 0.32)

Total (95% CI)		**588**		**571**	**100.0%**	**0.00 [-0.01, 0.02]**
Total events	7		3			

Heterogeneity: Tau² = 0.00; Chi² = 3.72, df = 3 (P = 0.29); I² = 19%
Test for overall effect: Z = 0.37 (P = 0.71)
Test for subgroup differences: Chi² = 0.93, df = 1 (P = 0.33), I² = 0%



Behaviour change (by dose) – Peto



Behaviour change (by condition)



Behaviour change (by condition) – Peto



Headache



Headache – Peto



SYSTEMIC vs. PLACEBO – Dermatologic

Integument

Study or Subgroup	Systemic Events	Systemic Total	Placebo Events	Placebo Total	Weight	Risk Difference M-H, Random, 95% CI
Bjornson 2004	2	359	0	361	83.2%	0.01 [-0.00, 0.01]
Csonka 2003	2	113	0	117	8.5%	0.02 [-0.01, 0.05]
Klassen 1998	0	64	0	65	8.3%	0.00 [-0.03, 0.03]
Total (95% CI)		**536**		**543**	**100.0%**	**0.01 [-0.00, 0.01]**
Total events	4		0			

Heterogeneity: Tau² = 0.00; Chi² = 0.87, df = 2 (P = 0.65); I² = 0%
Test for overall effect: Z = 1.41 (P = 0.16)



Integument – Peto

Study or Subgroup	Systemic Events	Systemic Total	Placebo Events	Placebo Total	Weight	Peto Odds Ratio Peto, Fixed, 95% CI
Bjornson 2004	2	359	0	361	50.1%	7.45 [0.47, 119.36]
Csonka 2003	2	113	0	117	49.9%	7.72 [0.48, 124.29]
Klassen 1998	0	64	0	65		Not estimable
Total (95% CI)		**536**		**543**	**100.0%**	**7.59 [1.07, 54.01]**
Total events	4		0			

Heterogeneity: Chi² = 0.00, df = 1 (P = 0.99); I² = 0%
Test for overall effect: Z = 2.02 (P = 0.04)



Integument (by dose)

Study or Subgroup	Systemic Events	Systemic Total	Placebo Events	Placebo Total	Weight	Risk Difference M-H, Random, 95% CI
1.71.1 Single dose						
Bjornson 2004	2	359	0	361	83.2%	0.01 [-0.00, 0.01]
Klassen 1998	0	64	0	65	8.3%	0.00 [-0.03, 0.03]
Subtotal (95% CI)		**423**		**426**	**91.5%**	**0.01 [-0.00, 0.01]**
Total events	2		0			

Heterogeneity: Tau² = 0.00; Chi² = 0.13, df = 1 (P = 0.72); I² = 0%
Test for overall effect: Z = 1.11 (P = 0.27)

1.71.2 Multi-dose						
Csonka 2003	2	113	0	117	8.5%	0.02 [-0.01, 0.05]
Subtotal (95% CI)		**113**		**117**	**8.5%**	**0.02 [-0.01, 0.05]**
Total events	2		0			

Heterogeneity: Not applicable
Test for overall effect: Z = 1.18 (P = 0.24)

Total (95% CI)		**536**		**543**	**100.0%**	**0.01 [-0.00, 0.01]**
Total events	4		0			

Heterogeneity: Tau² = 0.00; Chi² = 0.87, df = 2 (P = 0.65); I² = 0%
Test for overall effect: Z = 1.41 (P = 0.16)
Test for subgroup differences: Chi² = 0.65, df = 1 (P = 0.42), I² = 0%



Integument (by dose) – Peto



Integument (by condition)



Integument (by condition) – Peto



SYSTEMIC vs. PLACEBO – Endocrine/Metabolic & Musculoskeletal

Fluid & electrolyte abnormalities



Fluid & electrolyte abnormalities – Peto



Fluid & electrolyte abnormalities (by dose)



Fluid & electrolyte abnormalities (by dose) – Peto



Fluid & electrolyte abnormalities (by condition)



Fluid & electrolyte abnormalities (by condition) - Peto

Study or Subgroup	Systemic Events	Systemic Total	Placebo Events	Placebo Total	Weight	Peto Odds Ratio Peto, Fixed, 95% CI
1.68.1 Bronchiolitis						
Plint 2009	0	200	0	199		Not estimable
Plint 2009	1	200	0	201	17.6%	7.43 [0.15, 374.26]
Tagarro 2014	3	48	1	32	64.9%	1.91 [0.25, 14.72]
Subtotal (95% CI)		**448**		**432**	**82.4%**	**2.56 [0.42, 15.61]**
Total events	4		1			
Heterogeneity: Chi² = 0.36, df = 1 (P = 0.55); I² = 0%						
Test for overall effect: Z = 1.02 (P = 0.31)						
1.68.2 Croup						
Bjornson 2004	1	359	0	361	17.6%	7.43 [0.15, 374.47]
Eden 1967	0	25	0	25		Not estimable
Subtotal (95% CI)		**384**		**386**	**17.6%**	**7.43 [0.15, 374.47]**
Total events	1		0			
Heterogeneity: Not applicable						
Test for overall effect: Z = 1.00 (P = 0.32)						
Total (95% CI)		**832**		**818**	**100.0%**	**3.08 [0.60, 15.94]**
Total events	5		1			
Heterogeneity: Chi² = 0.60, df = 2 (P = 0.74); I² = 0%						
Test for overall effect: Z = 1.34 (P = 0.18)						
Test for subgroup differences: Chi² = 0.23, df = 1 (P = 0.63), I² = 0%						



SYSTEMIC vs. PLACEBO – Cardiovascular

Arrhythmia

Study or Subgroup	Systemic Events	Systemic Total	Placebo Events	Placebo Total	Weight	Risk Difference M-H, Random, 95% CI
Daugbjerg 1993	0	31	0	27	100.0%	0.00 [-0.07, 0.07]
Total (95% CI)		**31**		**27**	**100.0%**	**0.00 [-0.07, 0.07]**
Total events	0		0			

Heterogeneity: Not applicable
Test for overall effect: Z = 0.00 (P = 1.00)



Arrhythmia - Peto

Study or Subgroup	Systemic Events	Systemic Total	Placebo Events	Placebo Total	Weight	Peto Odds Ratio Peto, Fixed, 95% CI
Daugbjerg 1993	0	31	0	27		Not estimable
Total (95% CI)		**31**		**27**		**Not estimable**
Total events	0		0			

Heterogeneity: Not applicable
Test for overall effect: Not applicable



Hypertension

Study or Subgroup	Systemic Events	Systemic Total	Placebo Events	Placebo Total	Weight	Risk Difference M-H, Random, 95% CI
Buckingham 2002	0	22	0	19	0.4%	0.00 [-0.09, 0.09]
Corneli 2007	0	305	0	295	68.9%	0.00 [-0.01, 0.01]
Plint 2009	0	200	1	199	15.3%	-0.01 [-0.02, 0.01]
Plint 2009	1	200	0	201	15.5%	0.01 [-0.01, 0.02]
Total (95% CI)		**727**		**714**	**100.0%**	**0.00 [-0.01, 0.01]**
Total events	1		1			

Heterogeneity: Tau² = 0.00; Chi² = 1.02, df = 3 (P = 0.80); I² = 0%
Test for overall effect: Z = 0.00 (P = 1.00)



Hypertension – Peto

Study or Subgroup	Systemic Events	Systemic Total	Placebo Events	Placebo Total	Weight	Peto Odds Ratio Peto, Fixed, 95% CI
Buckingham 2002	0	22	0	19		Not estimable
Corneli 2007	0	305	0	295		Not estimable
Plint 2009	0	200	1	199	50.0%	0.13 [0.00, 6.79]
Plint 2009	1	200	0	201	50.0%	7.43 [0.15, 374.26]
Total (95% CI)		**727**		**714**	**100.0%**	**1.00 [0.06, 15.99]**
Total events	1		1			

Heterogeneity: Chi² = 2.01, df = 1 (P = 0.16); I² = 50%
Test for overall effect: Z = 0.00 (P = 1.00)



Hypertension (by dose)



Hypertension (by dose) - Peto



Congestive heart failure



Congestive heart failure - Peto

Study or Subgroup	Systemic Events	Total	Placebo Events	Total	Weight	Peto Odds Ratio Peto, Fixed, 95% CI
Eden 1967	0	25	0	25		Not estimable
Total (95% CI)		**25**		**25**		**Not estimable**
Total events	0		0			

Heterogeneity: Not applicable
Test for overall effect: Not applicable



SYSTEMIC vs. PLACEBO – General

General complaints



Study or Subgroup	Systemic Events	Systemic Total	Placebo Events	Placebo Total	Weight	Risk Difference M-H, Random, 95% CI
Kuyucu 2004	0	23	0	11	8.2%	0.00 [-0.13, 0.13]
Kuyucu 2004	0	23	0	12	9.3%	0.00 [-0.12, 0.12]
Plint 2009	23	200	22	199	34.2%	0.00 [-0.06, 0.07]
Plint 2009	15	200	16	201	48.3%	-0.00 [-0.06, 0.05]
Total (95% CI)		**446**		**423**	**100.0%**	**-0.00 [-0.04, 0.04]**
Total events	38		38			

Heterogeneity: Tau² = 0.00; Chi² = 0.05, df = 3 (P = 1.00); I² = 0%
Test for overall effect: Z = 0.04 (P = 0.97)

General complaints – Peto



Study or Subgroup	Systemic Events	Systemic Total	Placebo Events	Placebo Total	Weight	Peto Odds Ratio Peto, Fixed, 95% CI
Kuyucu 2004	0	23	0	11		Not estimable
Kuyucu 2004	0	23	0	12		Not estimable
Plint 2009	23	200	22	199	58.3%	1.05 [0.56, 1.94]
Plint 2009	15	200	16	201	41.7%	0.94 [0.45, 1.95]
Total (95% CI)		**446**		**423**	**100.0%**	**1.00 [0.62, 1.60]**
Total events	38		38			

Heterogeneity: Chi² = 0.05, df = 1 (P = 0.82); I² = 0%
Test for overall effect: Z = 0.00 (P = 1.00)

General complaints (by dose)



Study or Subgroup	Systemic Events	Systemic Total	Placebo Events	Placebo Total	Weight	Risk Difference M-H, Random, 95% CI
1.87.1 Single Dose						
Kuyucu 2004	0	23	0	11	8.2%	0.00 [-0.13, 0.13]
Kuyucu 2004	0	23	0	12	9.3%	0.00 [-0.12, 0.12]
Subtotal (95% CI)		**46**		**23**	**17.5%**	**0.00 [-0.09, 0.09]**
Total events	0		0			
1.87.2 Multi-Dose						
Plint 2009	23	200	22	199	34.2%	0.00 [-0.06, 0.07]
Plint 2009	15	200	16	201	48.3%	-0.00 [-0.06, 0.05]
Subtotal (95% CI)		**400**		**400**	**82.5%**	**-0.00 [-0.04, 0.04]**
Total events	38		38			
Total (95% CI)		**446**		**423**	**100.0%**	**-0.00 [-0.04, 0.04]**
Total events	38		38			

Heterogeneity: Tau² = 0.00; Chi² = 0.00, df = 1 (P = 1.00); I² = 0%
Test for overall effect: Z = 0.00 (P = 1.00)
Heterogeneity: Tau² = 0.00; Chi² = 0.05, df = 1 (P = 0.82); I² = 0%
Test for overall effect: Z = 0.04 (P = 0.97)
Heterogeneity: Tau² = 0.00; Chi² = 0.05, df = 3 (P = 1.00); I² = 0%
Test for overall effect: Z = 0.04 (P = 0.97)
Test for subgroup differences: Chi² = 0.00, df = 1 (P = 0.99), I² = 0%

General complaints (by dose) – Peto



SYSTEMIC vs. PLACEBO – Immune System

Immunosuppression

Study or Subgroup	Systemic Events	Systemic Total	Placebo Events	Placebo Total	Weight	Risk Difference M-H, Random, 95% CI
Connolly 1969	0	47	0	48	100.0%	0.00 [-0.04, 0.04]
Total (95% CI)		**47**		**48**	**100.0%**	**0.00 [-0.04, 0.04]**
Total events	0		0			

Heterogeneity: Not applicable
Test for overall effect: Z = 0.00 (P = 1.00)



Immunosuppression – Peto

Study or Subgroup	Systemic Events	Systemic Total	Placebo Events	Placebo Total	Weight	Peto Odds Ratio Peto, Fixed, 95% CI
Connolly 1969	0	47	0	48		Not estimable
Total (95% CI)		**47**		**48**		**Not estimable**
Total events	0		0			

Heterogeneity: Not applicable
Test for overall effect: Not applicable



INHALED vs. PLACEBO – Infection & Respiratory

Severe infections

Study or Subgroup	Inhaled Events	Inhaled Total	Placebo Events	Placebo Total	Weight	Risk Difference M-H, Random, 95% CI
Ducharme 2009	2	62	4	67	100.0%	-0.03 [-0.10, 0.04]
Total (95% CI)		**62**		**67**	**100.0%**	**-0.03 [-0.10, 0.04]**
Total events	2		4			

Heterogeneity: Not applicable
Test for overall effect: Z = 0.75 (P = 0.45)



Severe infections – Peto

Study or Subgroup	Inhaled Events	Inhaled Total	Placebo Events	Placebo Total	Weight	Peto Odds Ratio Peto, Fixed, 95% CI
Ducharme 2009	2	62	4	67	100.0%	0.54 [0.11, 2.77]
Total (95% CI)		**62**		**67**	**100.0%**	**0.54 [0.11, 2.77]**
Total events	2		4			

Heterogeneity: Not applicable
Test for overall effect: Z = 0.74 (P = 0.46)



Systemic infections

Study or Subgroup	Inhaled Events	Inhaled Total	Placebo Events	Placebo Total	Weight	Risk Difference M-H, Random, 95% CI
Daugbjerg 1993	0	29	0	27	84.6%	0.00 [-0.07, 0.07]
Ducharme 2009	18	62	20	67	15.4%	-0.01 [-0.17, 0.15]
Total (95% CI)		**91**		**94**	**100.0%**	**-0.00 [-0.06, 0.06]**
Total events	18		20			

Heterogeneity: Tau² = 0.00; Chi² = 0.03, df = 1 (P = 0.87); I² = 0%
Test for overall effect: Z = 0.04 (P = 0.97)



Systemic infections – Peto

Study or Subgroup	Inhaled Events	Inhaled Total	Placebo Events	Placebo Total	Weight	Peto Odds Ratio Peto, Fixed, 95% CI
Daugbjerg 1993	0	29	0	27		Not estimable
Ducharme 2009	18	62	20	67	100.0%	0.96 [0.45, 2.05]
Total (95% CI)		**91**		**94**	**100.0%**	**0.96 [0.45, 2.05]**
Total events	18		20			

Heterogeneity: Not applicable
Test for overall effect: Z = 0.10 (P = 0.92)



Lung/trachea

Study or Subgroup	Inhaled Events	Inhaled Total	Placebo Events	Placebo Total	Weight	Risk Difference M-H, Random, 95% CI
Ducharme 2009	13	62	10	67	100.0%	0.06 [-0.07, 0.19]
Total (95% CI)		**62**		**67**	**100.0%**	**0.06 [-0.07, 0.19]**
Total events	13		10			

Heterogeneity: Not applicable
Test for overall effect: Z = 0.89 (P = 0.37)



Lung/trachea – Peto

Study or Subgroup	Inhaled Events	Inhaled Total	Placebo Events	Placebo Total	Weight	Peto Odds Ratio Peto, Fixed, 95% CI
Ducharme 2009	13	62	10	67	100.0%	1.51 [0.61, 3.70]
Total (95% CI)		**62**		**67**	**100.0%**	**1.51 [0.61, 3.70]**
Total events	13		10			

Heterogeneity: Not applicable
Test for overall effect: Z = 0.89 (P = 0.37)



URT

Study or Subgroup	Inhaled Events	Inhaled Total	Placebo Events	Placebo Total	Weight	Risk Difference M-H, Random, 95% CI
Clavenna 2014	12	264	15	261	24.3%	-0.01 [-0.05, 0.03]
Daugbjerg 1993	0	29	0	27	7.7%	0.00 [-0.07, 0.07]
Ducharme 2009	10	62	9	67	2.3%	0.03 [-0.10, 0.15]
Johnson 1996	2	28	0	27	2.7%	0.07 [-0.04, 0.18]
Johnson 1998	0	48	0	49	22.3%	0.00 [-0.04, 0.04]
Klassen 1998	0	64	0	68	40.7%	0.00 [-0.03, 0.03]
Total (95% CI)		**495**		**499**	**100.0%**	**-0.00 [-0.02, 0.02]**
Total events	24		24			

Heterogeneity: Tau² = 0.00; Chi² = 2.12, df = 5 (P = 0.83); I² = 0%
Test for overall effect: Z = 0.04 (P = 0.97)



URT – Peto

Study or Subgroup	Inhaled Events	Inhaled Total	Placebo Events	Placebo Total	Weight	Peto Odds Ratio Peto, Fixed, 95% CI
Clavenna 2014	12	264	15	261	58.4%	0.78 [0.36, 1.70]
Daugbjerg 1993	0	29	0	27		Not estimable
Ducharme 2009	10	62	9	67	37.1%	1.24 [0.47, 3.27]
Johnson 1996	2	28	0	27	4.5%	7.40 [0.45, 121.47]
Johnson 1998	0	48	0	49		Not estimable
Klassen 1998	0	64	0	68		Not estimable
Total (95% CI)		**495**		**499**	**100.0%**	**1.03 [0.57, 1.85]**
Total events	24		24			

Heterogeneity: Chi² = 2.53, df = 2 (P = 0.28); I² = 21%
Test for overall effect: Z = 0.08 (P = 0.93)



URT (by dose)



URT (by dose) – Peto



URT (by condition)



URT (by condition) – Peto



Voice complaints



Voice complaints – Peto



Voice complaints (by condition)



Voice complaints (by condition) - Peto



INHALED vs. PLACEBO – GI

GI bleeding



GI bleeding – Peto



Vomiting



Vomiting – Peto



Vomiting (by dose)



Vomiting (by dose) – Peto



Vomiting (by condition)



Vomiting (by condition) - Peto



Diarrhea



Diarrhea – Peto



INHALED vs. PLACEBO – CNS & Behaviour

Behaviour change



Behaviour change – Peto



Behaviour change (by dose)



Behaviour change (by dose) – Peto



Behaviour change (by condition)



Behaviour change (by condition) – Peto



INHALED vs. PLACEBO – Dermatologic

Burn



Burn – Peto



Integument



Integument – Peto



Integument (by dose)



Integument (by dose) – Peto



Integument (by condition)



Integument (by condition) – Peto



INHALED vs. PLACEBO – Endocrine/Metabolic & Musculoskeletal

Growth – change from baseline, cm

Study or Subgroup	Inhaled Mean	Inhaled SD	Inhaled Total	Placebo Mean	Placebo SD	Placebo Total	Weight	Mean Difference IV, Random, 95% CI
Bacharier 2008	7.8	1.75	96	7.5	1.9	47	68.3%	0.30 [-0.35, 0.95]
Ducharme 2009	6.23	2.62	58	6.56	2.9	62	31.7%	-0.33 [-1.32, 0.66]
Total (95% CI)			**154**			**109**	**100.0%**	**0.10 [-0.47, 0.67]**

Heterogeneity: Tau² = 0.02; Chi² = 1.09, df = 1 (P = 0.30); I² = 9%
Test for overall effect: Z = 0.34 (P = 0.73)



Adrenal suppression

Study or Subgroup	Inhaled Events	Inhaled Total	Placebo Events	Placebo Total	Weight	Risk Difference M-H, Random, 95% CI
Hedlin 1999	5	6	4	10	100.0%	0.43 [0.01, 0.86]
Total (95% CI)		**6**		**10**	**100.0%**	**0.43 [0.01, 0.86]**
Total events	5		4			

Heterogeneity: Not applicable
Test for overall effect: Z = 2.00 (P = 0.05)



Adrenal suppression - Peto

Study or Subgroup	Inhaled Events	Inhaled Total	Placebo Events	Placebo Total	Weight	Peto Odds Ratio Peto, Fixed, 95% CI
Hedlin 1999	5	6	4	10	100.0%	5.21 [0.72, 37.57]
Total (95% CI)		**6**		**10**	**100.0%**	**5.21 [0.72, 37.57]**
Total events	5		4			

Heterogeneity: Not applicable
Test for overall effect: Z = 1.64 (P = 0.10)



INHALED vs. PLACEBO – Cardiovascular

Arrhythmia

Study or Subgroup	Inhaled Events	Inhaled Total	Placebo Events	Placebo Total	Weight	Risk Difference M-H, Random, 95% CI
Daugbjerg 1993	0	29	0	27	100.0%	0.00 [-0.07, 0.07]
Total (95% CI)		**29**		**27**	**100.0%**	**0.00 [-0.07, 0.07]**
Total events	0		0			

Heterogeneity: Not applicable
Test for overall effect: Z = 0.00 (P = 1.00)



Arrhythmia – Peto

Study or Subgroup	Inhaled Events	Inhaled Total	Placebo Events	Placebo Total	Weight	Peto Odds Ratio Peto, Fixed, 95% CI
Daugbjerg 1993	0	29	0	27		Not estimable
Total (95% CI)		**29**		**27**		**Not estimable**
Total events	0		0			

Heterogeneity: Not applicable
Test for overall effect: Not applicable



DEXAMETHASONE vs. OTHER STEROID – GI

Vomiting



Vomiting – Peto



Vomiting (by dose)



Vomiting (by dose) – Peto



Vomiting (by condition)



Vomiting (by condition) – Peto



Abdominal pain



Abdominal pain – Peto



Abdominal pain (by condition)



Abdominal pain (by condition) – Peto



DEXAMETHASONE vs. OTHER STEROID – CNS & Behaviour

Tremor/jitteriness

Study or Subgroup	Dexamethasone Events	Total	Other Steroid Events	Total	Weight	Risk Difference M-H, Random, 95% CI
Garbutt 2013	1	46	0	41	100.0%	0.02 [-0.04, 0.08]
Total (95% CI)		**46**		**41**	**100.0%**	**0.02 [-0.04, 0.08]**
Total events	1		0			

Heterogeneity: Not applicable
Test for overall effect: Z = 0.71 (P = 0.48)



Tremor/jitteriness – Peto

Study or Subgroup	Dexamethasone Events	Total	Other Steroid Events	Total	Weight	Peto Odds Ratio Peto, Fixed, 95% CI
Garbutt 2013	1	46	0	41	100.0%	6.63 [0.13, 336.21]
Total (95% CI)		**46**		**41**	**100.0%**	**6.63 [0.13, 336.21]**
Total events	1		0			

Heterogeneity: Not applicable
Test for overall effect: Z = 0.94 (P = 0.35)



Behaviour change

Study or Subgroup	Dexamethasone Events	Total	Other Steroid Events	Total	Weight	Risk Difference M-H, Random, 95% CI
Garbutt 2013	25	46	24	41	65.4%	-0.04 [-0.25, 0.17]
Gries 2000	10	14	14	16	34.6%	-0.16 [-0.45, 0.13]
Total (95% CI)		**60**		**57**	**100.0%**	**-0.08 [-0.25, 0.09]**
Total events	35		38			

Heterogeneity: Tau² = 0.00; Chi² = 0.45, df = 1 (P = 0.50); I² = 0%
Test for overall effect: Z = 0.96 (P = 0.33)



Behaviour change – Peto

Study or Subgroup	Dexamethasone Events	Total	Other Steroid Events	Total	Weight	Peto Odds Ratio Peto, Fixed, 95% CI
Garbutt 2013	25	46	24	41	81.4%	0.85 [0.36, 1.97]
Gries 2000	10	14	14	16	18.6%	0.38 [0.06, 2.21]
Total (95% CI)		**60**		**57**	**100.0%**	**0.73 [0.34, 1.56]**
Total events	35		38			

Heterogeneity: Chi² = 0.65, df = 1 (P = 0.42); I² = 0%
Test for overall effect: Z = 0.82 (P = 0.41)



Behaviour change (by condition)



Behaviour change (by condition) – Peto



Headache



Headache – Peto



Headache (by condition)



Headache (by condition) – Peto



DEXAMETHASONE vs. OTHER STEROID – Dermatologic

Phlebitis

Study or Subgroup	Dexamethasone Events	Dexamethasone Total	Other Steroid Events	Other Steroid Total	Weight	Risk Difference M-H, Random, 95% CI
Gries 2000	0	15	0	17	100.0%	0.00 [-0.11, 0.11]
Total (95% CI)		**15**		**17**	**100.0%**	**0.00 [-0.11, 0.11]**
Total events	0		0			

Heterogeneity: Not applicable
Test for overall effect: Z = 0.00 (P = 1.00)



Phlebitis – Peto

Study or Subgroup	Dexamethasone Events	Dexamethasone Total	Other Steroid Events	Other Steroid Total	Weight	Peto Odds Ratio Peto, Fixed, 95% CI
Gries 2000	0	15	0	17		Not estimable
Total (95% CI)		**15**		**17**		**Not estimable**
Total events	0		0			

Heterogeneity: Not applicable
Test for overall effect: Not applicable



DEXAMETHASONE vs. OTHER STEROID – Endocrine/Metabolic & Musculoskeletal

Fluid & electrolyte abnormalities



Fluid & electrolyte abnormalities – Peto



DEXAMETHASONE vs. OTHER STEROID – Cardiovascular

Arrhythmia

Study or Subgroup	Dexamethasone Events	Dexamethasone Total	Other Steroid Events	Other Steroid Total	Weight	Risk Difference M-H, Random, 95% CI
Altamimi 2006	0	56	0	54	100.0%	0.00 [-0.03, 0.03]
Total (95% CI)		**56**		**54**	**100.0%**	**0.00 [-0.03, 0.03]**
Total events	0		0			

Heterogeneity: Not applicable
Test for overall effect: Z = 0.00 (P = 1.00)



Arrhythmia – Peto

Study or Subgroup	Dexamethasone Events	Dexamethasone Total	Other Steroid Events	Other Steroid Total	Weight	Peto Odds Ratio Peto, Fixed, 95% CI
Altamimi 2006	0	56	0	54		Not estimable
Total (95% CI)		**56**		**54**		**Not estimable**
Total events	0		0			

Heterogeneity: Not applicable
Test for overall effect: Not applicable



Hypertension

Study or Subgroup	Dexamethasone Events	Dexamethasone Total	Other Steroid Events	Other Steroid Total	Weight	Risk Difference M-H, Random, 95% CI
Gries 2000	0	15	0	17	100.0%	0.00 [-0.11, 0.11]
Total (95% CI)		**15**		**17**	**100.0%**	**0.00 [-0.11, 0.11]**
Total events	0		0			

Heterogeneity: Not applicable
Test for overall effect: Z = 0.00 (P = 1.00)



Hypertension – Peto

Study or Subgroup	Dexamethasone Events	Dexamethasone Total	Other Steroid Events	Other Steroid Total	Weight	Peto Odds Ratio Peto, Fixed, 95% CI
Gries 2000	0	15	0	17		Not estimable
Total (95% CI)		**15**		**17**		**Not estimable**
Total events	0		0			

Heterogeneity: Not applicable
Test for overall effect: Not applicable



DEXAMETHASONE vs. OTHER STEROID – General

General complaints

Study or Subgroup	Dexamethasone Events	Dexamethasone Total	Other Steroid Events	Other Steroid Total	Weight	Risk Difference M-H, Random, 95% CI
Altamimi 2006	0	56	1	54	79.5%	-0.02 [-0.07, 0.03]
Garbutt 2013	3	46	2	41	20.5%	0.02 [-0.08, 0.11]
Total (95% CI)		**102**		**95**	**100.0%**	**-0.01 [-0.06, 0.03]**
Total events	3		3			

Heterogeneity: Tau² = 0.00; Chi² = 0.53, df = 1 (P = 0.47); I² = 0%
Test for overall effect: Z = 0.50 (P = 0.61)



General complaints – Peto

Study or Subgroup	Dexamethasone Events	Dexamethasone Total	Other Steroid Events	Other Steroid Total	Weight	Peto Odds Ratio Peto, Fixed, 95% CI
Altamimi 2006	0	56	1	54	17.4%	0.13 [0.00, 6.58]
Garbutt 2013	3	46	2	41	82.6%	1.35 [0.22, 8.15]
Total (95% CI)		**102**		**95**	**100.0%**	**0.90 [0.18, 4.61]**
Total events	3		3			

Heterogeneity: Chi² = 1.13, df = 1 (P = 0.29); I² = 11%
Test for overall effect: Z = 0.13 (P = 0.90)



General complaints (by condition)

Study or Subgroup	Dexamethasone Events	Dexamethasone Total	Other Steroid Events	Other Steroid Total	Weight	Risk Difference M-H, Random, 95% CI
3.6.1 Asthma						
Altamimi 2006	0	56	1	54	78.7%	-0.02 [-0.07, 0.03]
Subtotal (95% CI)		**56**		**54**	**78.7%**	**-0.02 [-0.07, 0.03]**
Total events	0		1			
Heterogeneity: Not applicable						
Test for overall effect: Z = 0.73 (P = 0.46)						
3.6.2 Croup						
Garbutt 2013	3	48	2	41	21.3%	0.01 [-0.08, 0.11]
Subtotal (95% CI)		**48**		**41**	**21.3%**	**0.01 [-0.08, 0.11]**
Total events	3		2			
Heterogeneity: Not applicable						
Test for overall effect: Z = 0.28 (P = 0.78)						
Total (95% CI)		**104**		**95**	**100.0%**	**-0.01 [-0.06, 0.03]**
Total events	3		3			

Heterogeneity: Tau² = 0.00; Chi² = 0.46, df = 1 (P = 0.50); I² = 0%
Test for overall effect: Z = 0.52 (P = 0.60)
Test for subgroup differences: Chi² = 0.35, df = 1 (P = 0.56), I² = 0%



General complaints (by condition) – Peto